Abstract 3277
Background
Cancer-related inflammation is a distinctive feature of the development and progression of PC. However, the relationship between the systemic inflammatory response and survival has not been evaluated as a predictive factor of chemotherapy. The aim of this study was to evaluate the prognostic and predictive value of a baseline SIRI based on peripheral neutrophil, monocyte, and lymphocyte counts in metastatic PC.
Methods
Retrospective review of 178 metastatic pancreatic cancer patients. Associations between overall survival (OS), time to progression (TTP), chemotherapy schedule and SIRI at diagnosis were analyzed.
Results
Median age 67 years, 52% were male. First line chemotherapy regimens: 41% Gemcitabine, 31% Gemcitabine plus Nab-Paclitaxel and 17% mFOLFIRINOX. Patients with SIRI<2.3x109 showed a statistically significant improvement in OS compared to SIRI≥2.3x109 [16 months versus 4.8 months, Hazard Ratio (HR) 2.87, Confidence Interval (CI) 95% 2.02-4.07, p < 0.0001] that was confirmed in multivariate analysis. In addition, patients with SIRI<2.3x109 showed a longer TTP (12 versus 6 months, HR 1.92, IC 95% 1.314-2.800, P = 0.001). Furthermore, we observed that patients with SIRI ≥2.3x109 are more likely to benefit from mFOLFIRINOX therapy. Patients with an elevated SIRI treated with mFOLFIRINOX versus Gemcitabine plus Nab-Paclitaxel and Gemcitabine showed a clinically and statistically significant difference in median OS of 17 months compared to 6 and 4 months respectively (p < 0.001). Conversely, the difference was not clinically significant in the SIRI<2.3x109 subgroup: 15.9 months versus 16.5 and 16, respectively.
Conclusions
An elevated SIRI (≥2.3x109) is an independent prognostic factor for survival in patients with metastatic pancreatic cancer. Patients with an elevated SIRI (≥2.3x109) show an increased benefit from mFOLFIRINOX in comparison to other first line chemotherapy regimens. These results raise the issue of appropriately selecting patients who would benefit of a more intensive first-line chemotherapy regimen.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4600 - Patterns and outcomes related to rapid progressive disease in a cohort of advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
Presenter: Lucio Ghiglione
Session: Poster Display session 3
Resources:
Abstract
3547 - Real World Outcomes of Immune-Related Adverse Events (irAEs) among Patients Receiving Immune Checkpoint Inhibitors (ICIs) in Hospital Settings
Presenter: Saby George
Session: Poster Display session 3
Resources:
Abstract
1124 - Sex-based heterogeneity of efficacy of anticancer immunotherapy
Presenter: Fabio Conforti
Session: Poster Display session 3
Resources:
Abstract
4133 - Comparative efficacy and safety of PD-1/PD-L1 inhibitors for patients with solid tumors: a systematic review and Bayesian network meta-analysis
Presenter: Qingyuan Huang
Session: Poster Display session 3
Resources:
Abstract
2548 - Excess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients
Presenter: Jacobo Rogado
Session: Poster Display session 3
Resources:
Abstract
2228 - Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma
Presenter: Antoine Italiano
Session: Poster Display session 3
Resources:
Abstract
2333 - Efficacy and safety of immune checkpoint inhibitors (ICIs) for treatment of advanced solid tumours in octogenarian patients
Presenter: Soraya Mebarki
Session: Poster Display session 3
Resources:
Abstract
4847 - Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies
Presenter: Aracelis Torres
Session: Poster Display session 3
Resources:
Abstract
2215 - Clinical outcomes of immune checkpoint inhibitors in older and younger patients with advanced solid tumours in a real-life setting
Presenter: Pauline Corbaux
Session: Poster Display session 3
Resources:
Abstract
2881 - Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Joaquin Mosquera Martinez
Session: Poster Display session 3
Resources:
Abstract